Clinical Trial Detail

NCT ID NCT02537444
Title ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

fallopian tube carcinoma

peritoneal carcinoma

ovary epithelial cancer

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult

No variant requirements are available.